Canakinumab (ACZ885) is a recombinant human anti-IL-1beta monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1beta, respectively. The mode of action of canakinumab is based on the neutralization of IL-1beta signaling, resulting in suppression of inflammation related to disorders of autoimmune origin.
Reinheit:
>99.0%
CAS Nummer:
[914613-48-2]
Target-Kategorie:
IL Receptor/Related
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten